Revenue
2022
2023
2024
2025
Estrella Immunopharma, Inc. (ESLA)
Price$0.6936Cached quote
Net income
2021
2022
2022
2023
2024
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2022
2023
2024
2024
2025
Financial statements
| 2025 | 2024 · Dec 31 | 2024 · Jun 30 | 2023 | 2022 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | — | $0 | — |
| Research & development | $10.2M | $2.9M | $4.1M | $10.5M | — | $1.4M | — |
| Operating expenses | $13.1M | $4.4M | $7.3M | $11.1M | $1.4M | $1.7M | $178,992 |
| Operating income | −$13.1M | −$4.4M | −$7.3M | −$11.1M | −$1.6M | −$1.7M | −$249,146 |
| EBITDA | −$13.1M | — | −$7.3M | −$11.1M | — | −$1.7M | — |
| Net income | −$13.1M | −$4.4M | −$7.3M | −$11.1M | −$996,104 | −$1.7M | −$247,718 |
| Basic EPSper basic share | -$0.35 | -$0.12 | -$0.27 | -$36.35 | — | -$0.05 | — |
| Diluted EPSper diluted share | -$0.35 | -$0.12 | -$0.27 | -$36.35 | — | -$0.05 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
ARMISTICE CAPITAL, LLC | 3.98M |
Xu Jiandong | 546.78K |
VANGUARD CAPITAL MANAGEMENT LLC | 416.85K |
Zhang Hong | 240.48K |
GEODE CAPITAL MANAGEMENT, LLC | 141.32K |
VANGUARD FIDUCIARY TRUST CO | 64.92K |
BlackRock, Inc. | 52.03K |
STATE STREET CORP | 43.25K |
RENAISSANCE TECHNOLOGIES LLC | 39.1K |
NORTHERN TRUST CORP | 34.86K |
US BANCORP \DE\ | 20K |
Tower Research Capital LLC (TRC) | 3.31K |
UBS Group AG | 1.72K |
TORONTO DOMINION BANK | 1.09K |
WOLVERINE ASSET MANAGEMENT LLC | 468 |
BARCLAYS PLC | 126 |
Caitong International Asset Management Co., Ltd | 2 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 7, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share | 1.0K | $1.33 | $1.3K | 265.5K |
| Sep 22, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share · indirect | 1.0K | $1.16 | $1.2K | 16.7K |
| Sep 11, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share | 100 | $1.04 | $104.00 | 264.6K |